Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A CLINICAL-EVALUATION OF RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA - A 10-WEEK, OPEN-LABEL, MULTICENTER TRIAL
Autore:
JESTE DV; KLAUSNER M; BRECHER M; CLYDE C; JONES R; ABUZZAHAB FS; AHMAD A; AHMED S; AINSLIE G; ALIDON G; JAMPALA VC; ANDRIULLI G; ASHLEIGH EA; AUKSTUOLIS J; BACON RJ; BADHIWALA SP; BAGRI KS; BALDWIN JD; BARDINELLI AJ; BARON D; BARTHOLOW G; BEACH RL; BERA RB; BERKEY R; BIRD LJ; BOYER W; ESCALONA R; CACCIOPPOLI G; TALIAFERRO J; CARTER RG; CENTRIC RW; CHARALAMPOUS KD; CHASTEK JW; CHAUHAN N; CHO SN; COHEN AJ; COHN CK; CORDER SL; CUERVO MS; CUTLER MO; DAMERA BR; HAMILTON RS; DANIELS K; DASKALOV Z; DAVID A; DAVIS H; DELEON J; DELLARIO AV; DIRKSEN JS; DOSSANTOS E; DOW TW; DOWNIE D; DRELL WK; EKHOLM C; ELIO E; FABRE L; FALCI T; FISHBEIN JH; FREER JH; FRENKEL D; FULLER W; GERHARDSTEIN R; GRACE J; GREINER T; GUPTA BK; HAMADANI HG; HARTFORD JT; HEGE DL; HICKS PB; HILL WJ; HOLINER J; HOLLAND PJ; HORNE RL; IBE IO; ISHAQUE S; IVORY PB; JACOBSON C; JAMIESON RC; JOHNSON CG; KENNEDY B; KESKINER A; KLING A; KLUGHEIT M; KOHLI AK; KOMARLA AK; LANIER P; LEONE NF; LILES JR; LU TC; MAHFOOZI H; MALEKPOUR B; MALONE DA; MANNAVA P; MANNING DB; MANSCHRECK T; MCLARNON MC; MCMINN MR; MEELEE D; MEGOWEN GL; MEHLER C; MERAYO HE; MIAN MA; MINGIONE DL; MITTAL D; MODIR K; MOON TK; MUNOZ RA; NADEL SM; NAGI K; NALLURI AC; NOORDSIJ AJ; ORELLANA E; PASTERNAK IM; PATEL D; PATWA VK; PETRIE WM; PINSKI G; PUESAN R; QADRI MK; RAFULS WA; RAICHMAN JA; RAMESHWAR ER; RAO TV; REBECK B; STUMPF A; REIST C; RHEW SS; RISBY ED; ROCK NL; ROSENBLATT S; ROSENSTOCK HA; ROSILLO R; ROSSON BA; ROY SK; RUIZ EG; SANCLEMENTE JP; SANDERS RQ; SANDLER NH; SCHLUETER J; SCHOOFF K; SHINDERMAN M; SOLOMON R; SPIVY DF; STEPHENS W; SWE NN; THOMPSON PM; THORNELOE WF; TIRANDAZ H; TUAN CH; TUCKER TA; UNFRIED GJ; VALKO TR; VEITS H; VILLALBA AE; VOLLMER S; WALKER P; WANG GL; WEAVER KE; WEICHBRODT G; WEISE CC; WEISS KJ; WELLSHEAR CC; YAPALATER AR; YERASI B; YOUNG AS; ZAKALA M; ZOBER JM; ZUKOF D;
Indirizzi:
UNIV CALIF SAN DIEGO,116A-1,3350 LA JOLLA VILLAGE DR SAN DIEGO CA 92161 VET AFFAIRS MED CTR SAN DIEGO CA 92161 JANSSEN RES FDN TITUSVILLE NJ 00000
Titolo Testata:
Psychopharmacology
fascicolo: 3, volume: 131, anno: 1997,
pagine: 239 - 247
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLOBAL ASSESSMENT SCALE; TARDIVE-DYSKINESIA; HALOPERIDOL;
Keywords:
ANTIPSYCHOTIC; PSYCHOSIS; NEGATIVE SYMPTOMS; EXTRAPYRAMIDAL SYMPTOMS; DYSKINESIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
D.V. Jeste et al., "A CLINICAL-EVALUATION OF RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA - A 10-WEEK, OPEN-LABEL, MULTICENTER TRIAL", Psychopharmacology, 131(3), 1997, pp. 239-247

Abstract

The efficacy and safety of risperidone have previously been demonstrated in controlled clinical trials in hospitalized chronic schizophrenia patients who met strict research criteria. The present study was designed to evaluate the efficacy and safety of risperidone in a heterogeneous patient population. Patients were enrolled in the study if they had a diagnosis of schizophrenia (DSM-III-R) with or without acute exacerbation. Of the 945 patients from 158 psychiatric centers who entered this phase IV study, 558 completed the 10-week trial. During week 1,the dose of risperidone was titrated to 6 mg/day, maintained there for 1 week, and then adjusted over a 4-week period as clinically necessary; the dose was then fixed for the final 4-week period. The mean doseof risperidone at endpoint was 5.9 mg/day. Patients were evaluated atbaseline and at weeks 2: 6, and 10, using Clinical Global Impression scale, Psychotic Symptoms Assessment scale, and Global Assessment of Functioning scale. Significant improvement in mean scores was found on each of these measures at endpoint. Comparable results were obtained at week 10 in treatment-resistant and non-treatment-resistant patients. Risperidone was generally well tolerated and the severity of extrapyramidal symptoms was significantly reduced at endpoint.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 07:29:58